Andreas Delker

发表

Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer

U. Haberkorn, G. Böning, C. Stief, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

The Influence of Early Measurements Onto the Estimated Kidney Dose in [177Lu][DOTA0,Tyr3]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors

G. Böning, P. Bartenstein, C. Zach, 2015, Molecular Imaging and Biology.

Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjects

Michael W. Weiner, Martin Dichgans, Peter Bartenstein, 2015, Neurobiology of Aging.

Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach

S. Ziegler, G. Böning, P. Bartenstein, 2018, EJNMMI Research.

Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [18F]-Florbetaben PET Quantitation in Alzheimer's Model Mice

P. Bartenstein, A. Rominger, J. Herms, 2016, Front. Neurosci..

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

G. Böning, C. Stief, P. Bartenstein, 2016, Oncotarget.

Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients

For the Alzheimer’s Disease Neuroimaging Initiative, O. Pogarell, P. Bartenstein, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [18F]-florbetaben PET

Jochen Herms, Harald Steiner, Karlheinz Baumann, 2014, NeuroImage.

In Vivo Mesenchymal Stem Cell Tracking with PET Using the Dopamine Type 2 Receptor and 18F-Fallypride

W. Mutschler, M. Schieker, G. Böning, 2014, The Journal of Nuclear Medicine.

Dose-Dependent Uptake of 3′-deoxy-3′-[18 F]Fluorothymidine by the Bowel after Total-Body Irradiation

G. Böning, C. Belka, K. Lauber, 2014, Molecular Imaging and Biology.

Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.

S. Greven, K. Ishii, O. Pogarell, 2018, Journal of Alzheimer's disease : JAD.

Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction

John Seibyl, Peter Bartenstein, Axel Rominger, 2015, NeuroImage.

Investigation of models with temporal and spatialinterference in image based dosimetry of 177Lu-labelled radioligand therapies

Andreas Delker, Andreas Delker, 2016 .

Longitudinal amyloid PET in mild cognitive impaired patients

A. Rominger, M. Brendel, Andreas Delker, 2014 .